Biotechnology

Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), for tr...

2022-12-21 08:00 3774

Sanisure Announces the Acquisition of a Leading Silicone Extrusion Facility in Twinsburg, Ohio

CAMARILLO, Calif., Dec. 21, 2022 /PRNewswire/ -- Sanisure, a leading, vertically-integrated player in the single- use bioprocessing technology space, is pleased to announce the acquisition of Medical Elastomer Development, Inc ("MED") a silicone extrusion facility from Q Holding, a 3i portfolio c...

2022-12-21 00:06 2802

AstraZenca, G42 Healthcare enter strategic partnership to manufacture pharmaceutical products in Abu Dhabi

ABU DHABI, UAE, Dec. 20, 2022 /PRNewswire/ -- Building on the ongoing efforts of the Department of Health –Abu Dhabi (DoH) in spearheading Abu Dhabi's healthcare ecosystem, AstraZeneca, a science-led biopharmaceutical and one of the top 10 biopharma companies globally, and G42 Healthcare, an AI-p...

2022-12-20 23:16 2932

Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia

CAMBRIDGE, Mass., Dec. 20, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) and the Australian Therapeutic ...

2022-12-20 20:00 3683

The Top 8 Best Places to Work in Philippines for 2022 revealed

MANILA, Philippines , Dec. 20, 2022 /PRNewswire/ -- Amway, Fujitsu, Multicare, Novo Nordisk, Diageo, Kusum, Schindler and Universal Robina are recognized as the top 8 best places to work inPhilippines for 2022 according to the annual prestigious "Best Places to Work" certification program.  Amwa...

2022-12-20 19:56 3541

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapie...

2022-12-19 23:07 3355

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board. He joins Prof. Jianzhu Chen of theMassach...

2022-12-19 22:00 2774

Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives

--The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Office (USPTO). The patent number is 11,541,071 -- The issued patent covers ASC10 and its derivatives, and their uses to treat virus infections including SARS-CoV-2, monkeypox virus and respiratory s...

2022-12-19 18:10 3757

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

* Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform * Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Gra...

2022-12-16 19:56 4239

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of ...

2022-12-16 14:49 6601

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of$150 million aggregate principal amount of its ...

2022-12-16 14:18 6083

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of$125 million aggregate principal amount of convertible...

2022-12-15 23:43 5325

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Ph...

2022-12-15 14:00 3798

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) for the company's IND appl...

2022-12-15 13:08 5265

XINGIMAGING and MITRO BIOTECH CO., LTD. to DELIVER FULL-SERVICE CRO OPERATIONS TO CHINA

NEW HAVEN, Conn., Dec. 15, 2022 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd. each highly recognized for drug development and imaging solutions, announce today that they will join forces to provide comprehensive contract research services inChina. The company will be a leading par...

2022-12-15 12:53 3172

CGTN: How China strengthens vaccine cooperation to battle COVID-19

BEIJING, Dec. 15, 2022 /PRNewswire/ -- Since the outbreak of COVID-19, the world has raced against time, battling the pandemic as it wreaked havoc across the globe. Developing safe and effective vaccines is one of the most crucial steps in the fight against the virus. For the last nearly three y...

2022-12-15 09:16 3922

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest M...

2022-12-15 08:00 7639

Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other m...

2022-12-15 08:00 5023

Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund

SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financing co-led by Eight Roads Ve...

2022-12-15 08:00 3932

Novavax Announces Proposed $125 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its c...

2022-12-15 05:39 5081
1 ... 118119120121122123124 ... 184